Ashley McEvoy - Nov 30, 2022 Form 4 Insider Report for JOHNSON & JOHNSON (JNJ)

Role
EVP, WW Chair, MedTech
Signature
Raavi K. Deol, as attorney-in-fact for Ashley McEvoy
Stock symbol
JNJ
Transactions as of
Nov 30, 2022
Transactions value $
-$7,546,950
Form type
4
Date filed
12/2/2022, 03:32 PM
Previous filing
Feb 17, 2022
Next filing
Feb 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNJ Common Stock Options Exercise $5.32M +73.3K +175.36% $72.54 115K Nov 30, 2022 Direct
transaction JNJ Common Stock Sale -$247K -1.4K -1.22% $176.09 114K Nov 30, 2022 Direct F1
transaction JNJ Common Stock Sale -$12.6M -71.9K -63.24% $175.46 41.8K Nov 30, 2022 Direct F2
holding JNJ Common Stock 2.7K Nov 30, 2022 By 401k F3
holding JNJ Common Stock 300 Nov 30, 2022 By ESOP F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNJ Employee Stock Options (Right to Buy) Options Exercise $0 -73.3K -100% $0.00* 0 Nov 30, 2022 Common Stock 73.3K $72.54 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $176.050 to $176.115. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed in multiple trades at prices ranging from $175.040 to $176.010. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (10/31/2022)
F4 Shares held by ESOP under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (10/31/2022)